Disappointment as NHS can't give 'world first' cancer drug.
WOMEN with ovarian cancer and mutations to their BRCA genes are still not being granted a "world-first drug" on the NHS, something the chief executive of the Institute of Cancer Research has said is "disappointing".
Professor Paul Workman was speaking after the National Institute for Health and Care Excellence (Nice) said it has opened a second consultation on the drug olaparib.
Nice said that, although it slows the progression of the disease for patients with some forms of ovarian cancer, the evidence that it can extend life is uncertain and health officials are not sure if it is cost effective.
Nice said the price the NHS is being asked to pay for olaparib is too high for the benefit it may provide to patients who have had fewer than three previous courses of platinum-based chemotherapy. Prof Workman said: "We remain disappointed that women with ovarian cancer and mutations to their BRCA genes are still not being granted this world-first drug on the NHS."